Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial.
Cruz LR, Baladrón I, Rittoles A, Díaz PA, Valenzuela C, Santana R, Vázquez MM, García A, Chacón D, Thompson D, Perera G, González A, Reyes R, Torres L, Pérez J, Valido Y, Rodriguez R, Vázquez-Bloomquist DM, Rosales M, Ramón AC, Pérez GV, Guillén G, Muzio V, Perera Y, Perea SE; ATENEA-Co-300 Group. Cruz LR, et al. ACS Pharmacol Transl Sci. 2020 Dec 11;4(1):206-212. doi: 10.1021/acsptsci.0c00175. eCollection 2021 Feb 12. ACS Pharmacol Transl Sci. 2020. PMID: 33615173 Free PMC article.
Efficacy of 30% silver diamine fluoride compared to atraumatic restorative treatment on dentine caries arrestment in primary molars of preschool children: A 12-months parallel randomized controlled clinical trial.
Vollú AL, Rodrigues GF, Rougemount Teixeira RV, Cruz LR, Dos Santos Massa G, de Lima Moreira JP, Luiz RR, Barja-Fidalgo F, Fonseca-Gonçalves A. Vollú AL, et al. Among authors: cruz lr. J Dent. 2019 Sep;88:103165. doi: 10.1016/j.jdent.2019.07.003. Epub 2019 Jul 4. J Dent. 2019. PMID: 31279925 Clinical Trial.
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Bachelot T, et al. Ann Oncol. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061. Ann Oncol. 2019. PMID: 30796821 Free article. Clinical Trial.
21 results